The NF-κB inhibition by deferasirox could prove to be an important therapeutic option in higher risk MDS patients, targeting blast cells in which increased NF-κB activity has been extensively demonstrated, and acting as a possible enhancer of chemosensitivity of the neoplastic clone. Here, NFKB1 is linked to myelodysplastic syndrome.